Form 4: Terns Pharmaceuticals Director Jeffrey Kindler Acquires Stock Options in Lieu of Cash Retainer
SEC Form 4
Director Jeffrey Kindler of Terns Pharmaceuticals acquired stock options in lieu of cash retainer fees, according to a Form 4 filing.
Summary
- Jeffrey Kindler, a director at Terns Pharmaceuticals, acquired 4,676 stock options on July 1, 2024.
- The options were granted in lieu of a $20,000 cash retainer fee for the third and fourth quarters of 2024, as per the Issuer's Non-Employee Director Compensation Policy.
- The exercise price of the options is $6.85.
- The options vest monthly, with full vesting by January 1, 2025, and expire on June 30, 2034.
- Following the transaction, Kindler directly owns 4,676 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine transaction related to director compensation. The director taking stock options instead of cash could be seen as a slightly positive signal.
Positives
- Director Kindler's decision to take stock options instead of cash may signal confidence in the company's future performance.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance beyond the vesting schedule of the options.
Industry Context
Director compensation packages often include stock options to align the interests of management with those of shareholders. This is a common practice in the pharmaceutical industry.
Comparison to Industry Standards
- Stock option grants are a typical component of executive and director compensation in the biotech and pharmaceutical industries.
- Companies like Gilead Sciences, Amgen, and Biogen also utilize stock options as part of their compensation packages to incentivize long-term value creation.
- The vesting schedule and exercise price are within the typical range for such grants.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholders if it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 07/01/2024 | Date of transaction: Jeffrey Kindler acquired stock options. |
| 01/01/2025 | Date when 100% of the shares subject to the option will be fully vested. |
| 06/30/2034 | Expiration date of the stock options. |
| 07/02/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.